Literature DB >> 16299334

Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region.

Robert Mabry1, Mridula Rani, Robert Geiger, Gene B Hubbard, Ricardo Carrion, Kathleen Brasky, Jean L Patterson, George Georgiou, B L Iverson.   

Abstract

Passive immunization has been successfully employed for protection against bacterial and viral infections for over 100 years. Immunoglobulin Fc regions play a critical role in the clearance of bacterial pathogens by mediating antibody-dependent and complement-dependent cytotoxicity. Here we show that antibody fragments engineered to recognize the protective antigen component of the B. anthracis exotoxin with high affinity and conjugated to polyethylene glycol (PEG) for prolonged circulation half-life confer significant protection against inhalation anthrax despite their lack of Fc regions. The speed and lower manufacturing cost of bacterially expressed PEGylated antibody fragments could provide decisive advantages for anthrax prophylaxis. Importantly, our results suggest that PEGylated antibody fragments may represent a unique approach for mounting a rapid therapeutic response to emerging pathogen infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299334      PMCID: PMC1307075          DOI: 10.1128/IAI.73.12.8362-8368.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

Review 1.  Antitoxins: novel strategies to target agents of bioterrorism.

Authors:  G Jonah A Rainey; John A T Young
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

2.  Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.

Authors:  D Borden Lacy; Darran J Wigelsworth; Roman A Melnyk; Stephen C Harrison; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

3.  Anthrax lethal factor inhibition.

Authors:  W L Shoop; Y Xiong; J Wiltsie; A Woods; J Guo; J V Pivnichny; T Felcetto; B F Michael; A Bansal; R T Cummings; B R Cunningham; A M Friedlander; C M Douglas; S B Patel; D Wisniewski; G Scapin; S P Salowe; D M Zaller; K T Chapman; E M Scolnick; D M Schmatz; K Bartizal; M MacCoss; J D Hermes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

Review 4.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Crystal structure of a complex between anthrax toxin and its host cell receptor.

Authors:  Eugenio Santelli; Laurie A Bankston; Stephen H Leppla; Robert C Liddington
Journal:  Nature       Date:  2004-07-04       Impact factor: 49.962

6.  Suppression of reaginic antibodies with modified allergens. II. Abrogation of reaginic antibodies with allergens conjugated to polyethylene glycol.

Authors:  W Y Lee; A H Sechon
Journal:  Int Arch Allergy Appl Immunol       Date:  1978

7.  Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries.

Authors:  Barrett R Harvey; George Georgiou; Andrew Hayhurst; Ki Jun Jeong; Brent L Iverson; Geoffrey K Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

8.  Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.

Authors:  Huguette Albrecht; Patricia A Burke; Arutselvan Natarajan; Cheng-Yi Xiong; Mark Kalicinsky; Gerald L DeNardo; Sally J DeNardo
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

9.  Selection of Bacillus anthracis isolates resistant to antibiotics.

Authors:  A Athamna; M Athamna; N Abu-Rashed; B Medlej; D J Bast; E Rubinstein
Journal:  J Antimicrob Chemother       Date:  2004-06-17       Impact factor: 5.790

10.  Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen.

Authors:  Darran J Wigelsworth; Bryan A Krantz; Kenneth A Christensen; D Borden Lacy; Stephen J Juris; R John Collier
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

View more
  30 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

2.  APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering.

Authors:  Ki Jun Jeong; Min Jeong Seo; Brent L Iverson; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

Review 3.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

4.  Targeting pili in enterococcal pathogenesis.

Authors:  Kenneth L Pinkston; Kavindra V Singh; Peng Gao; Nathaniel Wilganowski; Holly Robinson; Sukhen Ghosh; Ali Azhdarinia; Eva M Sevick-Muraca; Barbara E Murray; Barrett R Harvey
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

5.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

6.  Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.

Authors:  T J Van Blarcom; C Sofer-Podesta; J Ang; J L Boyer; R G Crystal; G Georgiou
Journal:  Gene Ther       Date:  2010-04-15       Impact factor: 5.250

7.  A single mouse monoclonal antibody, E58 modulates multiple IgE epitopes on group 1 cedar pollen allergens.

Authors:  Randall M Goldblum; Bo Ning; Barbara M Judy; Luis Marcelo F Holthauzen; Julius van Bavel; Atsushi Kamijo; Terumi Midoro-Horiuti
Journal:  Mol Immunol       Date:  2016-05-09       Impact factor: 4.407

8.  Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments.

Authors:  Anastasiya Yermakova; Nicholas J Mantis
Journal:  Toxicon       Date:  2013-04-17       Impact factor: 3.033

Review 9.  Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Authors:  Anette Schneemann; Marianne Manchester
Journal:  Future Microbiol       Date:  2009-02       Impact factor: 3.165

Review 10.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.